2026 Organizing Committee
Todd M. Morgan, MD
Co-Chair
Todd M. Morgan, MD is the Jack Lapides, MD Research Professor and Chief of Urologic Oncology at the University of Michigan, specializing in the evaluation and treatment of genitourinary malignancies. He is also Co-Director of the Weiser Center for Prostate Cancer at the University of Michigan. Dr. Morgan is a translational surgeon-scientist whose research spans preclinical laboratory-based research to prospective clinical trials. His laboratory is focused on developing blood-based tests that can guide precision-based treatments for prostate cancer in real time, and he is principal investigator of two large randomized controlled trials evaluating tissue-based biomarkers in men with localized prostate cancer. Dr. Morgan has been the recipient of Young Investigator Awards from the Prostate Cancer Foundation, Society for Urological Oncology, National Comprehensive Cancer Network (NCCN), and Society for Basic Urology Research. He has served on a number of national guideline committees, such as the AUA Salvage Therapy for Prostate Cancer Guidelines (Chair), Muscle-Invasive Bladder Cancer Guidelines, the AUA Advanced Prostate Cancer Guidelines, the NCCN Prostate Cancer Guidelines, the ASCO Localized Prostate Cancer Guideline, and the ASCO Molecular Markers for Prostate Cancer Guidelines. He is a past Chair of the ASCO Genitourinary Cancer Symposium. His research is supported by multiple sources and includes funding from the Department of Defense, National Cancer Institute, and the Prostate Cancer Foundation.
Amina Zoubeidi, PhD
Co-Chair
Amina Zoubeidi, PhD is a Canada Research Chair in Cancer Therapy Resistance at University of British Columbia and the Vancouver Prostate Centre. Her research aims to uncover how standard care of prostate cancer therapy targeting the androgen receptor induces treatment resistance and controls phenotypic plasticity, which has been associated with the clinically relevant problem of drug resistance in prostate cancer. Her research program is designed to identify and understand common signaling nodes responsible for the emergence of resistance to ultimately design the best combination therapy to guide clinical decisions. She received substantial funding from national (NCI-SPORE, DOD, PCF-USA, CIHR, TFRI, PCC). She is currently the leader of Terry Fox New Frontiers Program Project on understanding lineage plasticity in treatment resistance.
2025 Organizing Committee
Himisha Beltran, MD
Co-Chair
Dr. Beltran is an Associate Professor of Medicine at the Dana-Farber Cancer Institute. She is the Director of Translational Research within the Department of Medical Oncology, co-Director of the Center for Cancer Genomics, and co-PI of the Dana-Farber/Harvard Cancer Center Prostate Cancer SPORE. She also the head of a highly productive research group, focused on understanding the mechanisms underlying the development of neuroendocrine prostate cancer.
Himanshu Nagar, MD, MS
Co-Chair
Dr. Nagar is a radiation oncologist at Memorial Sloan Kettering Cancer Center and serves as the Director of the Genitourinary Program in the Department of Radiation Oncology. His focus is on clinical trials and translational research for genitourinary cancers. Additionally, he is a core member of the Alliance and NRG Oncology Genitourinary Cancer Committees.
2024 Founding Organizing Committee Members
Dr. Felix Feng
Chair
Dr. Feng is a professor of Radiation Oncology, Urology, and Medicine at the University of California, San Francisco. He serves as the Vice Chair for Translational Research in the Department of Radiation Oncology, and Associate Director for Translational Clinical Research in the Helen Diller Family Comprehensive Cancer Center. He is the director of the UCSF Benioff Initiative for Prostate Cancer Research.
Dr. Paul Nguyen
Co-Chair
Dr. Nguyen serves as the DF/BWCC Genitourinary Clinical Center Director for Radiation Oncology, Vice-Chair for Clinical Research in the Department of Radiation Oncology, Professor at Harvard Medical School, and Baldwin-Politi Distinguished Chair in Oncology at Brigham and Women's Hospital where he is also associate director of the Harvard Radiation Oncology Program residency.
Dr. Josh Lang
Co-Chair
Dr. Lang serves as the Associate Director of Translational Research at the University of Wisconsin Carbone Cancer Center, Vice Chair of Biomedical Research in the University of Wisconsin Department of Medicine, and Professor of Medicine in the Division of Hematology, Oncology and Palliative Care. He is a Vilas Distinguished Achievement Professor at the University of Wisconsin. He also serves as co-Director of the Physician Scientist Training Program in the Department of Medicine.